MEP Miapetra Kumpula-Natri

Ms Kumpula-Natri is a Member of the European Parliament representing Finland and the S&D. She is a member of the Committee on Industry, Research and Energy (ITRE) and a substitute member to the Committee on International Trade (INTA), where she is the standing rapporteur of the parliamentary monitoring group WTO rules on e-commerce. Ms Kumpula-Natri is also the first vice-chair of the European Parliament’s Delegation for relations with the United States of America (D-US) and has served as the first vice-chair of the Special Committee on Artificial Intelligence in a Digital Age (AIDA).

A strong advocate for gender equality and women in tech and digital cooperation, Ms Kumpula-Natri is the chair and founder of the UN Generation Equality Friendship Group in the European Parliament and a member of the European Parliament´s delegation to the Conference on the Future of Europe. Previously, Ms Kumpula-Natri was a member of the Finnish Parliament for 11 years and chaired the Grand Committee responsible for EU-Finland relations at the parliamentary level. She has also been a member of her hometown local council in Vaasa for 20 years.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More